The AACR Project GENIE Data Model, recently released by the AACR GENIE consortium, is an open-access tool designed to...
Just before the holidays, the U.S. Food and Drug Administration (FDA) had good news for the ovarian cancer research...
Guest Post by Anees B. Chagpar, MD, MPH, MBA Yale Cancer Center
Last week, the U.S. Food and Drug Administration (FDA) announced the approval of a new vaccine—Gardasil 9—that prevents infection...
As 2014 draws to a close, we look back on an exciting year during which we provided more than...
Earlier this month we witnessed another leap forward for immunotherapy when the FDA approved blinatumomab (Blincyto) for the treatment...
Adding the PI3-kinase inhibitor pictilisib to fulvestrant doubled progression-free survival for some women with advanced hormone-receptor positive breast cancer,...
After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope...
SABCS co-chair and AACR President Carlos L. Arteaga, MD, shares his views on this year's symposium and what the...
Guest Post by T.J. Sharpe Originally appeared on Philly.com's Patient #1 blog
Through think tanks, special conferences, and its Pediatric Cancer Working Group, the AACR is taking steps to establish childhood...